US EditionPublished • loading... • Updated
Valneva Reports Further Positive Phase 2 Safety and Immunogenicity Results for Lyme Disease Vaccine Candidate
Summary by Benzinga
2 Articles
2 Articles
Valneva Reports Further Positive Phase 2 Safety and Immunogenicity Results for Lyme Disease Vaccine Candidate
Strong immune response after third yearly booster dose in children and adults Significant anamnestic antibody response across all six serotypes No safety concerns observed in any age group by independent Data Monitoring Committee (DMC), consistent with previous booster results. Saint-Herblain (France), September 3rd, 2025 – Valneva SE (NASDAQ:VALN, PARIS:VLA) announced positive immunogenicity and safety data from the ongoing Phase 2 study of Ly…
·New York, United States
Read Full Article
https://www.tradingsat.com/valneva-FR0004056851/actualites/valneva-after-un-revers-sur-son-serum-counter-le-chikungunya-aux-states-unis-valneva-resurrection-with-prositive-for-son-vaccin-anti-lyme-1145628.html
Coverage Details
Total News Sources2
Leaning Left0Leaning Right0Center1Last UpdatedBias Distribution100% Center
Bias Distribution
- 100% of the sources are Center
100% Center
C 100%
Factuality
To view factuality data please Upgrade to Premium
